Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Rigel Pharmaceuticals, Inc. (RIGL)

0.74   -0.011 (-1.45%) 11-28 11:16
Open: 0.75 Pre. Close: 0.7509
High: 0.75 Low: 0.73
Volume: 227,131 Market Cap: 128(M)

Technical analysis

as of: 2022-11-28 10:51:51 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.89     One year: 0.95
Support: Support1: 0.67    Support2: 0.55
Resistance: Resistance1: 0.76    Resistance2: 0.81
Pivot: 0.74
Moving Average: MA(5): 0.76     MA(20): 0.74
MA(100): 1.14     MA(250): 1.86
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 56     %D(3): 64.1
RSI: RSI(14): 40
52-week: High: 3.51  Low: 0.63
Average Vol(K): 3-Month: 2,681 (K)  10-Days: 1,181 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RIGL ] has closed above bottom band by 37.7%. Bollinger Bands are 69% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.77 - 0.78 0.78 - 0.78
Low: 0.71 - 0.72 0.72 - 0.72
Close: 0.74 - 0.75 0.75 - 0.76

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Headline News

Sun, 27 Nov 2022
Is faded flag the only design option for veteran plates? | Ask the DMV - The Providence Journal

Sun, 20 Nov 2022
What forms would I fill out to change my registration? | Ask the DMV - The Providence Journal

Fri, 11 Nov 2022
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Thu, 10 Nov 2022
Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology - Yahoo Finance

Thu, 03 Nov 2022
Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition - Yahoo Finance

Thu, 03 Nov 2022
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 173 (M)
Shares Float 172 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 77.6 (%)
Shares Short 5,960 (K)
Shares Short P.Month 7,630 (K)

Stock Financials

EPS -0.5
EPS Est Next Qtl -0.16
EPS Est This Year -0.61
EPS Est Next Year -0.44
Book Value (p.s.) -0.12
Profit Margin (%) -96.3
Operating Margin (%) -92.1
Return on Assets (ttm) -32.8
Return on Equity (ttm) -553.8
Qtrly Rev. Growth -3.1
Gross Profit (p.s.) 0.41
Sales Per Share 0.49
EBITDA (p.s.) -0.46
Qtrly Earnings Growth 0
Operating Cash Flow -71 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -1.48
PEG Ratio -0.1
Price to Book value -6.13
Price to Sales 1.48
Price to Cash Flow -1.8

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.